Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Purpura, Thrombocytopenic, Idiopathic 3Lymphoma 3Pheochromocytoma 1Ovarian Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Liver Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Kidney Neoplasms 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

fostamatinib 3romiplostim 2eltrombopag 2Inosine Triphosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Purpura, Thrombocytopenic, Idiopathic × fostamatinib × Clear all
NCT02077192 2023-12-11

Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Rigel Pharmaceuticals

Phase 3 Completed
123 enrolled 11 charts 1 FDA

Purpura, Thrombocytopenic, Idiopathic

NCT02076399 2019-02-12

FIT

Rigel Pharmaceuticals

Phase 3 Completed
76 enrolled 17 charts 1 FDA

Purpura, Thrombocytopenic, Idiopathic

NCT02076412 2019-01-25

FIT

Rigel Pharmaceuticals

Phase 3 Completed
74 enrolled 17 charts 1 FDA

Purpura, Thrombocytopenic, Idiopathic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡